ABVC BioPharma (NASDAQ:ABVC) Issues Earnings Results, Beats Estimates By $0.37 EPS

ABVC BioPharma (NASDAQ:ABVC) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.37, Zacks reports.

ABVC BioPharma Price Performance

Shares of NASDAQ:ABVC traded down $0.02 during mid-day trading on Wednesday, reaching $0.96. 282,216 shares of the company were exchanged, compared to its average volume of 105,262. ABVC BioPharma has a 1 year low of $0.88 and a 1 year high of $3.40. The firm’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $1.35. The firm has a market cap of $25.49 million, a price-to-earnings ratio of -2.40 and a beta of 0.57.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ABVC BioPharma currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after buying an additional 6,017 shares during the period. Citadel Advisors LLC purchased a new stake in shares of ABVC BioPharma in the 3rd quarter valued at $48,000. Finally, Millennium Management LLC acquired a new position in ABVC BioPharma during the 3rd quarter worth about $60,000. 11.38% of the stock is currently owned by institutional investors and hedge funds.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.